BRPI0410445A - inibidores de amida de ácido pirrolopiridina-2-carboxìlico de glicogênio fosforilase - Google Patents

inibidores de amida de ácido pirrolopiridina-2-carboxìlico de glicogênio fosforilase

Info

Publication number
BRPI0410445A
BRPI0410445A BRPI0410445-5A BRPI0410445A BRPI0410445A BR PI0410445 A BRPI0410445 A BR PI0410445A BR PI0410445 A BRPI0410445 A BR PI0410445A BR PI0410445 A BRPI0410445 A BR PI0410445A
Authority
BR
Brazil
Prior art keywords
glycogen phosphorylase
pyrrolopyridine
carboxylic acid
acid amide
inhibitors
Prior art date
Application number
BRPI0410445-5A
Other languages
English (en)
Inventor
Stuart Edward Bradley
Thomas Martin Krulle
Peter John Murray
Martin James Procter
Robert John Rowley
Colin Peter Sambrook Smith
Gerard Hugh Thomas
Karen Lesley Schofield
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of BRPI0410445A publication Critical patent/BRPI0410445A/pt
Publication of BRPI0410445B1 publication Critical patent/BRPI0410445B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"INIBIDORES DE AMIDA DE áCIDO PIRROLOPIRI-DINA-2-CARBOXìLICO DE GLICOGêNIO FOSFORILASE". A presente invenção refere-se a compostos representados pela fórmula (I) ou seus sais farmaceuticamente aceitáveis, que são inibidores de fosforilase de glicogênio e que são úteis no tratamento profilático ou terapêutico de diabetes, hiperglicemia, hipercolesterolemia, hiperinsulinemia, hiperlipidemia, hipertensão, ateroesclerose ou isquemia de tecido, por exemplo, isquemia miocárdica e como cardioprotetores.
BRPI0410445-5A 2003-05-21 2004-05-20 Pyrrolopyridine-2-carboxylic acid amide inhibitor compound of glycogen phosphorylase, pharmaceutical composition comprising the same, process for its production and intermediate compounds BRPI0410445B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47237503P 2003-05-21 2003-05-21
US60/472,375 2003-05-21
US55125604P 2004-03-08 2004-03-08
US60/551,256 2004-03-08
PCT/US2004/016243 WO2004104001A2 (en) 2003-05-21 2004-05-20 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase

Publications (2)

Publication Number Publication Date
BRPI0410445A true BRPI0410445A (pt) 2006-05-30
BRPI0410445B1 BRPI0410445B1 (pt) 2017-11-28

Family

ID=33479321

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410445-5A BRPI0410445B1 (pt) 2003-05-21 2004-05-20 Pyrrolopyridine-2-carboxylic acid amide inhibitor compound of glycogen phosphorylase, pharmaceutical composition comprising the same, process for its production and intermediate compounds

Country Status (16)

Country Link
EP (1) EP1636224B1 (pt)
JP (2) JP2006528702A (pt)
KR (1) KR101120935B1 (pt)
AT (1) ATE473974T1 (pt)
AU (1) AU2004240946B8 (pt)
BR (1) BRPI0410445B1 (pt)
CA (1) CA2525502C (pt)
DE (1) DE602004028122D1 (pt)
EA (1) EA009215B1 (pt)
IL (1) IL171851A (pt)
MA (1) MA27809A1 (pt)
MX (1) MXPA05012547A (pt)
NO (1) NO332265B1 (pt)
NZ (1) NZ543482A (pt)
UA (1) UA84146C2 (pt)
WO (1) WO2004104001A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7989634B2 (en) * 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
DE602005023965D1 (de) 2004-03-08 2010-11-18 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
JP2007531744A (ja) * 2004-04-05 2007-11-08 武田薬品工業株式会社 ６−アザインドール化合物
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
WO2006059165A1 (en) 2004-12-02 2006-06-08 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
JP2008521873A (ja) 2004-12-02 2008-06-26 プロシディオン・リミテッド ピロロピリジン−２−カルボン酸アミド類
EP1948597A1 (en) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CA2631695A1 (en) * 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-b]pyridine derivatives as h3 receptor modulators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008063842A2 (en) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2010045188A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP5959075B2 (ja) * 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
US8513244B2 (en) 2011-05-31 2013-08-20 Theravance, Inc. Neprilysin inhibitors
JP5885832B2 (ja) 2011-05-31 2016-03-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
JP2015530990A (ja) 2012-08-17 2015-10-29 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺虫剤および殺ダニ剤としてのアザインドールカルボキサミドおよびアザインドールチオカルボキサミド
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9A INHIBITOR
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
KR20230169977A (ko) * 2021-03-10 2023-12-18 빈시어 바이오사이언시스, 인크. Usp30 억제제 및 이의 용도
CN115894373B (zh) * 2022-10-27 2025-08-01 常州大学 N-取代苄基吡唑衍生物在作为β2肾上腺素受体调节剂、拮抗剂和激动剂的应用
WO2023165168A1 (zh) * 2022-10-27 2023-09-07 常州大学 吡唑类衍生物作为β2肾上腺素受体别构调节剂,拮抗剂和激动剂的应用
CN115745891B (zh) * 2022-11-10 2025-08-01 常州大学 吡唑衍生物在作为β2-肾上腺素受体拮抗剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
WO1995033720A1 (en) * 1994-06-06 1995-12-14 The Green Cross Corporation Novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof
CA2223625C (en) * 1995-06-06 2003-06-03 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2224062C (en) * 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
MY114711A (en) * 1995-06-06 2002-12-31 Pfizer Substituted n-(indole-2-carbonyl)-b-alanmamides and derivatives as antidiabetic agents
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
ES2211454T3 (es) * 1999-09-30 2004-07-16 Pfizer Products Inc. Pirrolilamidas como inhibidores de la colageno fosforilasa.
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
WO2004039807A1 (en) * 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine and pyridoindolizine derivatives

Also Published As

Publication number Publication date
EA200501645A1 (ru) 2006-06-30
JP5669691B2 (ja) 2015-02-12
NZ543482A (en) 2009-02-28
KR101120935B1 (ko) 2012-03-05
NO332265B1 (no) 2012-08-13
MXPA05012547A (es) 2006-05-25
KR20060069792A (ko) 2006-06-22
WO2004104001A2 (en) 2004-12-02
AU2004240946A1 (en) 2004-12-02
EA009215B1 (ru) 2007-12-28
JP2011252005A (ja) 2011-12-15
AU2004240946B2 (en) 2011-09-08
CA2525502A1 (en) 2004-12-02
ATE473974T1 (de) 2010-07-15
EP1636224B1 (en) 2010-07-14
NO20055305D0 (no) 2005-11-10
EP1636224A2 (en) 2006-03-22
JP2006528702A (ja) 2006-12-21
MA27809A1 (fr) 2006-03-01
UA84146C2 (ru) 2008-09-25
AU2004240946B8 (en) 2012-01-12
IL171851A (en) 2011-08-31
WO2004104001A3 (en) 2005-03-03
NO20055305L (no) 2005-12-15
DE602004028122D1 (de) 2010-08-26
BRPI0410445B1 (pt) 2017-11-28
CA2525502C (en) 2012-12-18

Similar Documents

Publication Publication Date Title
BRPI0410445A (pt) inibidores de amida de ácido pirrolopiridina-2-carboxìlico de glicogênio fosforilase
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
JO2282B1 (en) Oxazole derivatives
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
BR0004582A (pt) Pirrolil-amidas bicìclicas como inibidores de glicogênio-fosforilase
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
NO20082496L (no) Pyrazinderivater
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
ATE384058T1 (de) Thiazolderivate
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
GB0413087D0 (en) Therapeutic compounds
WO2006011050A3 (en) Pyridine derivatives
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
NO20082445L (no) Neuropeptid-2 reseptor-agonister
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
ATE483708T1 (de) Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
WO2005085194A3 (en) Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
WO2004037166A3 (en) Therapeutic guanidines
TW200509941A (en) Pharmaceutical solution composition

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2568 DE 2020-03-24